





Mr. McLean made a motion that the Board approve year two of Project #776 by Dr. Albrigo in the amount of \$68,430. Seconded by Mr. Black, the motion passed unanimously. This project will include strobilurin treatments side by side with the plant growth regulator treatments.

Dr. Browning reported that the request from the CPDC and Board resulted in a meeting with NuFarm Americas, Inc. A field tour of ongoing trials allowed Dr. Stephanie Slinski, antimicrobials project manager and Dr. Browning to observe the ongoing evaluation of antibiotics against HLB being conducted by NuFarm. Dr. Browning introduced Mr. Craig Noll, Regional Account Manager for NuFarm, to begin NuFarm's presentation to the Board. Mr. Noll introduced Mr. Bewlay, NuFarm Business Development Manager, who gave an overview of NuFarm, an international plant protection and seed supplier that develops better solutions for plants. Ms. Larochelle reported on functions by their U.S. Development and Regulatory Teams which has handled over 600 registrations and 700 products, including herbicides, insecticides, fungicides and bactericides for agricultural use. Dr. Bob Bruss, Technical Services Manager, outlined where NuFarm stands at this time with the development of antibiotics for citrus HLB. Mr. Black asked what the Foundation can do to assist NuFarm. He stated the Foundation is looking for speed, not competition, in the search for a solution. He encouraged NuFarm and AgroSource to work together, and encouraged they continue their dialog with Dr. Browning and Dr. Slinski. NuFarm will work with Dr. Browning and expects to submit a proposal in the next few weeks.

Dr. Browning reported the CPD Quarterly Report is included with the meeting materials, summarizing progress toward the goals set for this year. The active projects were reviewed at the CPD meeting and Dr. Browning asked that questions on specific projects be directed to the relevant Project Managers. Discussion followed on Dr. Ehsani's thermal therapy project, refining time and temperature requirements for most effective thermal treatment. Regarding the status of the GRAS-like compound evaluations, a team is being put together to plan regulatory strategy meetings.

**Industry Research Coordinating Committee:** Chairman Wayne Simmons had nothing to report.

**COO Report:** Dr. Browning reported that four Board members' current terms will end December 31<sup>st</sup>. CRDF will be communicating with those members and their appointing organizations.

The Federal funding MAC is advancing decisions on the proposals received from stakeholder topic suggestions.

**Future CRDF Meetings:**

- Board of Directors meeting –December 9, 2014

With no further business, the meeting was adjourned at 11:40 a.m.

Minutes submitted by Jerry Newlin